anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
To have an impact on the premature mortality of African American smokers, effective treatment for smokers across the smoking continuum must be identified. Varenicline, the leading first-line medication for tobacco use treatment, triples the likelihood of long-term abstinence relative to placebo in those smoking \>10 cpd. To date, efficacy of varenicline has not been established in African American smokers or light smokers. The long-term goal of this research is to advance treatment for all African American smokers in order to reduce tobacco-related disease and death. Our primary objective is to evaluate the efficacy of varenicline for tobacco use treatment among 500 African American smokers, including a full range of cpd, within a double-blind, placebo-controlled, randomized clinical trial. We will randomize participants in a 3:2 ratio to receive varenicline (1 mg bid; n=300) or placebo (n=200) for 12 weeks, along with individualized health education counseling for all participants. Our specific aims are to evaluate the efficacy of varenicline to promote abstinence in African American smokers across the continuum of smoking level, to examine efficacy in light smokers and also in moderate to heavy smokers, and to describe biopsychosocial characteristics of this group and evaluate in relation to abstinence. This innovative study will provide the first placebo-controlled evaluation of varenicline in the full spectrum of African American smokers, and the first to examine varenicline in light smokers. Findings will contribute to advancing effective treatment for African American smokers and for light smokers, and enhancing individualized treatment. Increased treatment efficacy will have major impact on reducing tobacco-related morbidity and mortality in this high-risk population.
1,217,303. Water-soluble tetracycline complexes. I. MARCUS. 12 June, 1967, No. 29967/69. Heading C2A. A novel water-soluble complex of a tetracycline and methyleneamino-salicylic acid or a salt thereof, is prepared by reacting in a solvent a tetracycline with the said acid or its salt. The complexes are said to be simple addition compounds; in the case of tetracycline itself the complex has the formula The preferred salt is that of sodium, and the reaction is suitably carried out in methanol, under an inert atmosphere (e.g. nitrogen) in the absence of light. The complex separates as a precipitate which is filtered off, washed with methanol and dried. The product is anhydrous and may be hydrated by allowing it to stand in moist air. The complex is unstable in aqueous solutions, but its stability is increased by increasing the concentration of the solution. The complexes react with streptomycin, neomycin or dihydrostreptomycin in solution (e.g. in ethanol) to liberate the tetracycline and form a corresponding addition compound with the reacting antibiotic. Pharmaceutical compositions having antibiotic activity comprise the tetracyclinemethyleneamino-salicylic acid complex or its physiologically acceptable salt together with a pharmaceutical carrier or diluent; the compositions may be in forms suitable for parenteral, oral or rectal administration.
Integrity, control and regulation of the urinary tract are subject to a complex neuronal regulation, in which portions of the sympathetic, parasympathetic and somatic nervous system are involved. The spinal cord plays a central role in regulation and serves as a transmitter for the motor and sensory pathways. Bladder dysfunction followed by renal dysfunction was the most frequent cause of death in patients with spinal cord injuries/diseases (paraplegia) as recently as half a decade ago. Thanks mainly to diagnostic and therapeutic advances made in neuro-urology, urological problems are no longer life-limiting. A vital role is played not only by the actual function of the urinary tract but also by the complex interactions in patients living with paraplegia. Issues such undertreated hyperactivity of the detrusor muscle with autonomous dysregulation, incontinence with secondary skin changes, or insufficient hand function to perform intermittent catheterisation must be evaluated in an interdisciplinary approach. Spinal cord injury/disease implies numerous functional disorders and secondary impairments of the organism. In addition to bladder function, sexual dysfunction also plays a crucial role. Especially in younger patients who sustain paraplegia before or during the family planning phase, this disruption and limitation is an essential reason for reduced quality of life. Neurogenic intestinal function plays an additional crucial role with regard to quality of life and management of everyday life. In recent years, the range of neuro-urological topics has expanded significantly. The focus of our work shifted from being merely on the urinary tract and urodynamics. In particular, the diagnostic investigation and treatment of neurogenic intestinal dysfunction is increasingly in the hands of neuro-urologists. The complex presentation of paraplegia involves an interaction of bladder, intestinal and sexual dysfunction in a way that these influence one another. Therefore, the sustained care and re-integration of these patients essentially includes lifelong and regular neuro-urological care in a paraplegia centre. Last but not least, it is exactly these neuro-urological topics such as urinary tract infections, urinary and intestinal incontinence and faecal impaction, which most commonly lead to re-hospitalisation.
All enrolled participants will be allocated to this arm (single-arm study). Study participants will undergo 68Ga-NOTA-MAL-NB1417 PET/CT scan.
In pathological worry, the tendency to assess situations and experiences in a very negative way even when it is possible the situation may turn out to be neutral or even positive is suggested to fuel worry. This type of "mental habit" can maintain worry and cause people a lot of distress. Cognitive bias modification of interpretations (CBM-I) involves repeatedly and actively listening to descriptions of ambiguous scenarios that resolve in a benign fashion. CBM-I has shown promise at reducing the tendency to make negative interpretations when presented with ambiguous information as well as improving worry and low mood. However, further research is needed to optimize the protocol for individuals who engage in pathological worry. One such way to improve the task is using imagery. In this proof-of-concept experiment, the investigators are looking at whether having participants use imagery while practicing CBM-I for one week leads to greater improvements in worry and worry-related processes compared to the standard protocol without imagery instructions and compared to a neutral control condition. This study will also investigate dosage effects of CBM-I training by investigating changes in worry over the intervention period using a daily diary assessment.

Potential participants will be asked to complete a telephone screen. Those who meet eligibility criteria will be invited to our laboratory at Ryerson University. After completing pre-intervention outcome measures, participants will be randomly assigned to one of three conditions: (1) a condition where people imagine themselves in scenarios they listen to; (2) a condition where people listen to the scenarios without instruction to use imagery; and (3) a condition in which people listen to passages of non-emotional situations. Participants will be asked to complete their respective training for 7 days (60 scenarios/day). There will be two follow-up visits; one after participants complete their training and another two weeks following completion of the training. All of the outcome measures will be assessed pre-intervention, post-intervention and at the 2-week follow-up. Past week worry will also be assessed at a 1-week follow-up via a link that will be emailed. During the 1-week intervention period participants will also track their worry 3 times per day via a link that will be emailed to them.

The present experiment will provide answers to important questions about the therapeutic potential of imagery enhanced CBM compared to standard CBM for pathological worry. Moreover, this study will shed light on dosing effects of the intervention.
AIM: The development of robotic assistance has made dissection and suturing in the deep pelvis much easier. The augmented quality of the images and the articulation of the robotic arms have also enabled a more precise dissection. The aim of this study is to present the data on robotic-assisted ventral mesh rectopexy procedures in a university hospital and examine the literature in terms of mesh erosion.
METHOD: The electronic databases Pubmed, Embase and Cochrane were searched. Studies from January 2004 until January 2023 in the English language were included. Studies which included fewer than 10 patients were excluded. Laparoscopic or robotic-assisted ventral mesh rectopexies were included. Mesh erosion rates following laparoscopic or robotic-assisted ventral mesh rectopexies were measured.
RESULTS: Overall, the systematic review presents 5911 patients from 43 studies who underwent laparoscopic ventral mesh rectopexy compared with 746 patients treated with robotic-assisted ventral mesh rectopexy from six studies and our centre. Mesh erosion was rare in both groups; however, the prevalence was greater in the laparoscopy group (0.90% vs. 0.27%).
CONCLUSION: The mesh erosion rates are very low with robotic-assisted ventral mesh rectopexy. For precise results, more studies and experience in robotic surgery are required.
A novel treatment regimen is described for the control and elimination of cancer cell populations including cancer stem cells. The disclosed protocol consists of a pretreatment step followed by a treatment step. The pretreatment step sensitizes cancer cells to apoptosis by altering their intracellular oxidation-reduction state via reduced glutathione depletion. The treatment step involves the sequential administration of a cancerostatic dicarbonyl compound to induce apoptosis. The use of nanoparticle delivery systems further enhances both the pharmacokinetic and pharmacodynamic properties of the pretreatment compounds and the cancerostatic dicarbonyls. Since the pretreatment and treatment compounds are carefully selected and delivered, normal cells are not affected and side effects are kept to a minimum.
The invention relates to a bone strengthening drug. The bone strengthening drug comprises 10g of Herbal Ephedrae, 15g of pod of Chinese scholar tree, 10g of Ligusticum wallichii, 15g of Radix Clematidis, 15g of Divaricate Saposhnikovia Root, 20g of Fructus Viticis, 10g of Chinese magnoliavine, 8g of mulberry bark, 12g of Atractylodes lancea, 12g of ginseng and Polygonum multiflorum, 3g of dahurian angelica root, 5g of sophora flavescens and 10g of Radix Aucklandiae. The above formula is suitable for damp arthralgia and surface rheumatism, Herbal Ephedrae, Radix Clematidis, Divaricate Saposhnikovia Root and dahurian angelica root are used to remove wind and dampness in order to treat damp arthralgia, and Atractylodes lancea has the efficacy of strengthening spleen and eliminating dampness. Dampness is formed with heat, so sophora flavescens, Chinese scholar tree and Fructus Viticis are used to eliminate dampness by bitter and eliminate hotness by coldness. Mulberry bark has the efficacy of excreting water and eliminating swelling. Warm pathogen and stiction exist, so Radix Aucklandiae and Ligusticum wallichii are used to move qi and invigorate blood circulation, and ginseng, Chinese magnoliavine and Polygonum multiflorum are used to tonify qi and yin. All above medicines are combined to form a dampness eliminating, wind dispelling and healthy energy strengthening product, and is a proper patent medicine for treating damp arthralgia. The bone strengthening drug has the efficacy of dispelling wind and eliminating dampness, and stimulating blood circulation and relieving pains, and has very good curative effects on wind-cold-damp arthralgia, acroanesthesia, bone and muscle inability, and difficult walking.
Participants will receive a single subcutaneous (SC) dose of etanercept on Day 1 in Period 1 followed by single intravenous (IV) infusion of nipocalimab on Day 29, SC administration of etanercept followed by an IV infusion of nipocalimab on Day 43 and then a single dose of nipocalimab IV infusion on Day 57 in Period 2 of Part 1. There will be a wash-out period of 28 days between Day 1 of Period 1 and Day 29 of Period 2 in Part 1.
Eighty patients with American Society of Anesthesiologists（ASA） Ⅰ-Ⅲ older than 80 years are randomly assigned to 2 groups: a lumbar and sacral plexus block(LS) group with 20ml 0.5% ropivacaine at lumbar plexus(level L3-4) and 10ml 0.5%ropivacaine at sacral plexus; a lumbar, sacral plexus and paravertebral nerve block(LSP) group with 20ml 0.5% ropivacaine at lumbar plexus(level L3-4) , 10ml 0.5%ropivacaine at sacral plexus and 10ml 0.5%ropivacaine at paravertebral nerve(level L1). The target-controlled propofol infusion is started immediately after positioning the patient on the operating table. The initial target concentration was 0.5μg/mL. The infusion rate is adjusted every 5min by increasing or decreasing the target concentration by 0.2μg/mL steps based on the patients' respiratory rate(RR), blood pressure(BP), heart rate(HR), and level of sedation(score of 5 on Ramsay Sedation Scale ). The minimal, maximal, optimal target concentration, cumulative propofol dose, frequency of spontaneous movement and incidences of associated complications are recorded. Patients were phoned for followup and questioned for activity status in one year. If the patients were dead, date of death; if they survived, daily living activity questioned.
The pulse based-diet will include meals prepared with dry peas, lentils, chickpeas, and beans. Two meals will be supplied daily for 16 weeks to those participants on the pulse-based diet program. Meals will contain approximately 90g dried peas, 225 g chickpeas or beans, or 150g lentils.
Independent molecular and immunologic investigations strengthen the association between mycobacterial antigens and sarcoidosis pathogenesis. Molecular analysis of sarcoidosis granulomas reveals the presence of Mycobacterium tuberculosis complex (MTB) DNA and proteins that are significantly absent from granulomatous controls. Mycobacterial DNA has been detected in cutaneous sarcoidosis lesions, in addition to systemic immune responses against mycobacterial antigens. Due to the association between sarcoidosis and mycobacterial antigens, we postulated that broad spectrum antimycobacterial therapy could lead to restoration of T cell function and clinical improvement of chronic cutaneous sarcoidosis lesions. We investigated the safety and efficacy of Concomitant Levofloxacin, Ethambutol, Azithromycin, and Rifampin (CLEAR) therapy among chronic cutaneous sarcoidosis subjects, with change in lesion diameter from baseline to completion of 8 weeks of therapy as the primary endpoint; we assessed for decreases in granuloma burden, if granulomas were evident upon histologic examination. Change in modified Sarcoidosis Activity Severity Index (SASI) was the secondary endpoint.
Tracking and monitoring athletic activity offers individuals with additional motivation to continue such behavior. An individual may track his or her athletic activity by completing goals. These goals may be represented by real-world objects such as food items, landmarks, buildings, statues, other physical structures, toys and the like. Each object may correspond to an athletic activity goal and require an amount of athletic activity to complete the goal. For example, a donut goal object may correspond to an athletic activity goal of burning 350 calories. The user may progress from goal object to goal object. Goal objects may increase in difficulty (e.g., amount of athletic activity required) and might only be available for selection upon completing an immediately previous goal object, a number of goal objects, an amount of athletic activity and the like.
In recent decades, improvements in the treatment of pediatric cancer patients have resulted in increased survival rates. Consequentially, clinicians now pay more attention to the quality of life of these patients, both during and after treatment. Functional abilities have an important role in the quality of life and these skills can be compromised by the tumor itself or by anti-neoplastic treatments. A recent Cochrane review regarding rehabilitation and motor activity in this population has documented the effectiveness of exercise in children with cancer. Furthermore, to improve the rehabilitation care of pediatric cancer patients it is important to broaden the research by structuring multi-center trials, which allow the collection of longitudinal data. Objective, repeatable, specific, and sensitive rehabilitation assessment tools are needed, to define the functional status of the patient and to measure the motor outcomes. The psychometric properties of a measurement are closely linked to the specific population in which the measurement is used. Currently, there are two validated assessment tools for children/adolescents with cancer used to evaluate functional abilities: The Gross Motor Function Scale-Acute Lymphoblastic Leukemia (GMFM-ALL) and the Motor Performance in Pediatric Oncology (MOON). The ladder has the merit of being structured to evaluate the motor skills of children/adolescents affected by various forms of cancer but it also presents some limits. This test does not investigate functional abilities in a rehabilitation optic and it requires the use of specific materials that can reduce its usability in multicenter trials. The GMFM-ALL scale is a modified version of the Gross Motor Function Measure 88 (GMFM-88) Scale. This scale is specific only for children/adolescents with Lymphoblastic Leukemia and it mainly evaluates motor skills that require a high functional level (i.e. jumps, running), possessed neither by younger children nor by those who show major physical impairments or during specific phases of cancer treatment, such as palliative care.

The GMFM-88 scale is a rehabilitation assessment tool that was originally created to investigate functional abilities in children affected by cerebral palsy (CP) and has subsequently been validated for other populations of pediatric patients. It was also used to evaluate functional abilities in some studies conducted on pediatric cancer patients. Some aspects make this tool easily applicable in multicenter studies: it does not require any material to be administered nor a specific certified training to use it and, lastly, it comprises all principal motor skills including the basic ones (i.e. lying and rolling on the ground).
PCT No. PCT/JP93/00039 Sec. 371 Date Jul. 14, 1995 Sec. 102(e) Date Jul. 14, 1995 PCT Filed Jan. 14, 1993 PCT Pub. No. WO94/15969 PCT Pub. Date Jul. 12, 1994The present invention relates to a gene fragment coding for a variable region of an antibody having a neutralizing activity against human immunodeficiency virus (HIV) and a process for preparing the same. A mouse-human chimeric antibody and a mouse-human reshaped antibody having a neutralizing activity against HIV can be prepared by obtaining a specific nucleotide sequence of a gene fragment coding for a variable region of H chain and L chain of an antibody having a neutralizing activity against HIV, and then artificially fusing DNAs synthesized based on these nucleotide sequences with a gene coding for a human immunoglobulin. The novel recombinant anti-HIV antibody of the present invention is useful for treatment and prevention of AIDS.
An exhaust manifold including a manifold body made of a first material and at least one heat shield insert provided inside the manifold body and made of a second material. The first material is a low cost material and the second material is a higher grade, temperature-resistant material. The manifold body includes a plurality of runners, collector and an outlet. The shield insert is preferably provided in the collector region adjacent to the outlet. The heat shield insert may have a curved sheet configuration or a tubular configuration depending on applications. The heat shield properly insulates the manifold body from the exhaust gas to protect the manifold body. The exhaust manifold, which is made from a combination of different materials, provides a more cost-effective solution in high temperature applications.
Patients receive high-dose vorinostat PO at 48, 27, and 3 hours prior to surgery. Beginning 2-6 weeks later, patients receive vorinostat PO QD on days 1-3 in weeks 1-2and undergo fractionated stereotactic body radiation therapy on days 1-5 in weeks 1-2. Treatment continues in the absence of disease progression or unacceptable toxicity.
The invention discloses a formula of a Hui-nationality Chinese herbal radix sophorae subprostratae-rhizoma curcumae esophageal cancer treating pill and a preparation method thereof. The medicine is a green high-tech Chinese herbal medicine for treating esophageal cancer. The preparation method comprises the following steps: mixing Chinese herbal medicines such as radix sophorae subprostratae, rhizoma curcumae, glabrous sarcandra herb, japanese thistle herb or root, etc. according to a certain ratio, adding water and decocting, extracting, concentrating and pelleting to obtain traditional Chinese medicine pills, which are used for mainly treating esophageal cancer as well as treating digestive cancers such as pharyngolaryngeal cancer, gastric cancer, colorectal cancer, etc. The invention has the characteristics of moderate medicinal odour and dosage. The selected medicines are proved through pharmacology experiments of modern medicine to be capable of treating cancers. The medicine can fundamentally improve body functions at low cost and prevent cell cancerization so as to recover body health.
While the patient in the sitting position, the T7-T8 interspace can be identified. Then, skin infiltration with 2 ml of 1% lidocaine will be performed. Then, an 18-G Tuohy needle with a 20-G catheter (Perifix®, B.Braun, Germany) will be inserted through, and the epidural space will be located using the loss of resistance approach, then the patient will be given (5-10 mL) of bupivacaine 0.25% and rested into the supine position.
The invention relates to an antibacterial peptide mutant Sub168-QC/R, a recombinant strain and application thereof, belonging to the fields of genetic engineering and biotechnology, wherein the amino acid sequence of the antibacterial peptide mutant Sub168-QC/R is shown as SEQ ID NO.1, and the nucleotide sequence is shown as SEQ ID NO. 2. The invention also provides recombinant vectors and recombinant strains comprising SEQ ID NO. 2. The antibacterial peptide mutant Sub168-QC/R has higher inhibitory activity on various pathogenic bacteria such as escherichia coli, staphylococcus aureus and the like than the original antibacterial peptide Sub168, and has higher stability on trypsin. In addition, the antibacterial peptide mutant Sub168-QC/R also shows good thermostability, pH stability and pepsin stability. The mutant related by the invention has great advantages and potential in preparing novel antibacterial agents and application thereof.